Sanders Morris Harris’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.43M | Sell |
6,198
-1,404
| -18% | -$1.43M | 4.31% | 7 |
|
|
2026
Q1 | $6.99M | Buy |
+7,602
| New | +$7.71M | 1.11% | 19 |
|
|
2025
Q4 | – | Sell |
-7,606
| Closed | -$5.8M | – | 179 |
|
|
2025
Q3 | $5.8M | Buy |
7,606
+1,283
| +20% | +$955K | 0.77% | 17 |
|
|
2025
Q2 | $4.93M | Sell |
6,323
-3,058
| -33% | -$2.38M | 1.18% | 11 |
|
|
2025
Q1 | $7.69M | Sell |
9,381
-322
| -3% | -$268K | 1.19% | 13 |
|
|
2024
Q4 | $7.56M | Sell |
9,703
-137
| -1% | -$113K | 1.13% | 12 |
|
|
2024
Q3 | $8.72M | Sell |
9,840
-2
| -0% | -$1.8K | 1.45% | 11 |
|
|
2024
Q2 | $8.91M | Sell |
9,842
-2
| -0% | -$1.6K | 1.46% | 11 |
|
|
2024
Q1 | $7.66M | Buy |
9,844
+6,644
| +208% | +$4.73M | 1.41% | 9 |
|
|
2023
Q4 | $1.99M | Sell |
3,200
-6,776
| -68% | -$3.96M | 0.98% | 27 |
|
|
2023
Q3 | $5.33M | Sell |
9,976
-19
| -0.2% | -$9.79K | 1.1% | 12 |
|
|
2023
Q2 | $4.66M | Buy |
9,995
+3,205
| +47% | +$1.34M | 1.03% | 17 |
|
|
2023
Q1 | $2.33M | Sell |
6,790
-3,200
| -32% | -$1.08M | 0.81% | 14 |
|
|
2022
Q4 | $3.65M | Sell |
9,990
-6
| -0.1% | -$2.13K | 1.38% | 12 |
|
|
2022
Q3 | $3.23M | Sell |
9,996
-4
| -0% | -$1.27K | 0.79% | 22 |
|
|
2022
Q2 | $3.24M | Sell |
10,000
-12
| -0.1% | -$3.6K | 0.71% | 27 |
|
|
2022
Q1 | $2.87M | Sell |
10,012
-17
| -0.2% | -$4.38K | 0.56% | 35 |
|
|
2021
Q4 | $2.75M | Sell |
10,029
-124
| -1% | -$31.4K | 0.48% | 39 |
|
|
2021
Q3 | $2.35M | Sell |
10,153
-11
| -0.1% | -$2.71K | 0.43% | 48 |
|
|
2021
Q2 | $2.35M | Sell |
10,164
-15
| -0.1% | -$3.01K | 0.46% | 43 |
|
|
2021
Q1 | $1.89M | Sell |
10,179
-15
| -0.1% | -$2.93K | 0.4% | 46 |
|
|
2020
Q4 | $1.77M | Sell |
10,194
-14
| -0.1% | -$2.09K | 0.4% | 50 |
|
|
2020
Q3 | $1.52M | Buy |
10,208
+2,578
| +34% | +$399K | 0.41% | 53 |
|
|
2020
Q2 | $1.25M | Buy |
+7,630
| New | +$1.17M | 0.61% | 29 |
|
|
2020
Q1 | – | Sell |
-12,736
| Closed | -$1.67M | – | 239 |
|
|
2019
Q4 | $1.67M | Buy |
12,736
+47
| +0.4% | +$5.45K | 0.38% | 73 |
|
|
2019
Q3 | $1.4M | Hold |
12,689
| – | – | 0.34% | 73 |
|
|
2019
Q2 | $1.41M | Buy |
12,689
+4,953
| +64% | +$583K | 0.37% | 65 |
|
|
2019
Q1 | $1M | Sell |
7,736
-412
| -5% | -$50.1K | 0.49% | 41 |
|
|
2018
Q4 | $943K | Buy |
8,148
+28
| +0.3% | +$3.13K | 0.52% | 38 |
|
|
2018
Q3 | $871K | Sell |
8,120
-394
| -5% | -$39.4K | 0.41% | 48 |
|
|
2018
Q2 | $726K | Hold |
8,514
| – | – | 0.34% | 50 |
|
|
2018
Q1 | $659K | Hold |
8,514
| – | – | 0.28% | 62 |
|
|
2017
Q4 | $719K | Hold |
8,514
| – | – | 0.3% | 49 |
|
|
2017
Q3 | $728K | Sell |
8,514
-120
| -1% | -$9.84K | 0.31% | 63 |
|
|
2017
Q2 | $711K | Sell |
8,634
-850
| -9% | -$69.3K | 0.29% | 49 |
|
|
2017
Q1 | $797K | Sell |
9,484
-500
| -5% | -$40K | 0.29% | 58 |
|
|
2016
Q4 | $734K | Buy |
9,984
+417
| +4% | +$31.1K | 0.34% | 44 |
|
|
2016
Q3 | $768K | Buy |
9,567
+483
| +5% | +$38.7K | 0.23% | 63 |
|
|
2016
Q2 | $715K | Sell |
9,084
-1,193
| -12% | -$89.8K | 0.17% | 120 |
|
|
2016
Q1 | $740K | Buy |
+10,277
| New | +$778K | 0.13% | 151 |
|
Other funds holding LLY
SC
ONB
GIM
CRM
VNIM
CNB
Sanders Morris Harris's LLY Position: Q2 2026 in Review
Sanders Morris Harris reduced its Eli Lilly (LLY) stake by 18% in Q2 2026, selling an estimated $1.43M and leaving 6,198 shares worth $7.43M. The position accounts for 4.31% of the portfolio, ranked #7.
Sanders Morris Harris first reported a position in LLY in Q1 2016 and has held it in 40 quarters since. The position peaked at $8.91M in Q2 2024. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Sanders Morris Harris held 6,198 shares of Eli Lilly worth $7.43M as of Q2 2026.
- Sanders Morris Harris sold 1,404 Eli Lilly shares in Q2 2026, an estimated $1.43M.
- Eli Lilly made up 4.31% of Sanders Morris Harris's portfolio in Q2 2026, its #7 holding.
- Sanders Morris Harris first reported a position in Eli Lilly in Q1 2016 and has held it in 40 quarters since.
- Sanders Morris Harris's Eli Lilly position peaked at $8.91M in Q2 2024.
- 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.